Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06005129 · ClinicalTrials.gov registry record · NA
Personality Change Study for Borderline Personality Disorder
A NA study of Borderline Personality Disorder, sponsored by Shannon E. Sauer-Zavala.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06005129: Active NA study of Borderline Personality Disorder, sponsored by Shannon E. Sauer-Zavala.
NCT06005129 is a NA study of Borderline Personality Disorder that is active but no longer recruiting, run by Shannon E. Sauer-Zavala. The registered enrollment target is 30 participants, below the 106-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06005129, a NA study of Borderline Personality Disorder, is active but no longer recruiting, sponsored by Shannon E. Sauer-Zavala.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Participants with borderline personality disorder will undergo an a 2 - 4 week baseline assessment to determine level of outcomes of interest in the absence of treatment. After the baseline period, participants will receive six weekly 50-60-minute treatment sessions. After the 6 treatment sessions, participants will complete a 4-week follow-up period to determine the sustainability of the treatment module.
Primary Outcome
Change in borderline personality disorder symptoms will be measured using Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) - clinician-rated version. Scores range from 0-36; higher scores indicate greater severity of borderline personality disorder symptoms
Conditions Studied
Interventions
- BEHAVIORAL Personality-Based Therapy
Study Locations (1)
Kentucky
- Clinic for Emotional Health at the University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-15 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What the registry record for NCT06005129 still lists
NCT06005129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 106-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which Personality-Based Therapy is the first listed.
NCT06005129 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06005129 about?
NCT06005129 is a clinical study titled "Personality Change Study for Borderline Personality Disorder". Participants with borderline personality disorder will undergo an a 2 - 4 week baseline assessment to determine level of outcomes of interest in the absence of treatment. After the baseline period, participants will receive six weekly 50-60-minute treatment sessions. After the 6 treatment sessions, ...
What is the current status of trial NCT06005129?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-09-15. Estimated completion is 2026-03-31.
What conditions does trial NCT06005129 study?
This clinical trial studies the following conditions: Borderline Personality Disorder.
What interventions are being tested in trial NCT06005129?
The interventions under investigation include: Personality-Based Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06005129?
This trial is sponsored by Shannon E. Sauer-Zavala, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06005129 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Personality Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06005129's enrollment target sits among peer trials
30 12th of 16 higher than 4 of 16 other Borderline Personality Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Borderline Personality Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
RECRUITING · NA
-
Cognitive Reappraisal Training for Borderline Personality (BPD)
RECRUITING · NA
-
Treatment of Borderline Personality Disorder With rTMS
RECRUITING · NA
-
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
RECRUITING · NA
-
PILOT Phase: BPD Study
ACTIVE NOT RECRUITING · NA
-
Neurofeedback for Borderline Personality Disorder
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI